AU2014330781B2 - Compounds for affinity chromatography and for extending the half-life of a therapeutic agent - Google Patents
Compounds for affinity chromatography and for extending the half-life of a therapeutic agent Download PDFInfo
- Publication number
- AU2014330781B2 AU2014330781B2 AU2014330781A AU2014330781A AU2014330781B2 AU 2014330781 B2 AU2014330781 B2 AU 2014330781B2 AU 2014330781 A AU2014330781 A AU 2014330781A AU 2014330781 A AU2014330781 A AU 2014330781A AU 2014330781 B2 AU2014330781 B2 AU 2014330781B2
- Authority
- AU
- Australia
- Prior art keywords
- substituted
- unsubstituted
- salt
- compound according
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361885146P | 2013-10-01 | 2013-10-01 | |
| US61/885,146 | 2013-10-01 | ||
| US201462025994P | 2014-07-17 | 2014-07-17 | |
| US62/025,994 | 2014-07-17 | ||
| PCT/IB2014/064998 WO2015049651A1 (en) | 2013-10-01 | 2014-10-01 | Compounds for affinity chromatography and for extending the half-life of a therapeutic agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014330781A1 AU2014330781A1 (en) | 2016-04-07 |
| AU2014330781B2 true AU2014330781B2 (en) | 2017-05-04 |
Family
ID=51743521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014330781A Ceased AU2014330781B2 (en) | 2013-10-01 | 2014-10-01 | Compounds for affinity chromatography and for extending the half-life of a therapeutic agent |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9809558B2 (https=) |
| EP (1) | EP3052483B1 (https=) |
| JP (1) | JP2016534984A (https=) |
| KR (1) | KR20160060660A (https=) |
| CN (1) | CN105593222B (https=) |
| AU (1) | AU2014330781B2 (https=) |
| BR (1) | BR112016007371A2 (https=) |
| CA (1) | CA2925862A1 (https=) |
| ES (1) | ES2721098T3 (https=) |
| RU (1) | RU2016117052A (https=) |
| SG (1) | SG11201601870VA (https=) |
| WO (1) | WO2015049651A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170066839A1 (en) * | 2015-09-08 | 2017-03-09 | Merck Patent Gmbh | Novel affinity chromatography media for removal of anti-a and/or anti-b antibodies |
| US10697982B2 (en) | 2015-09-08 | 2020-06-30 | Merck Patent Gmbh | Methods of evaluating quality of a chromatography media which binds anti-A or anti-B antibodies |
| US10697983B2 (en) | 2015-09-08 | 2020-06-30 | Merck Patent Gmbh | Methods of evaluating quality of media suitable for removing anti-A or anti-B antibodies |
| JPWO2018181738A1 (ja) * | 2017-03-30 | 2020-02-13 | 日立化成株式会社 | 分離材 |
| CN112996801A (zh) * | 2018-11-26 | 2021-06-18 | 北卡罗来纳州大学 | 用于捕获宿主细胞蛋白的肽配体 |
| KR20210109552A (ko) | 2018-12-21 | 2021-09-06 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 이중특이적 단백질 |
| CA3164134A1 (en) | 2019-12-06 | 2021-06-10 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofurans as modulators of sodium channels |
| SI4347031T1 (sl) | 2021-06-04 | 2026-01-30 | Vertex Pharmaceuticals Incorporated | N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov |
| BR112023026747A2 (pt) | 2021-06-18 | 2024-03-12 | Aligos Therapeutics Inc | Métodos e composições para direcionamento de pd-l1 |
| CA3240346A1 (en) | 2021-12-16 | 2023-06-22 | Aligos Therapeutics, Inc. | Methods and compositions for targeting pd-l1 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH187973A4 (de) * | 1973-02-09 | 1977-03-31 | Hoechst Ag | Verfahren zum optischen Aufhellen von Textilmaterialien |
| US4722896A (en) | 1981-01-26 | 1988-02-02 | The Beth Israel Hospital Association | Method for affinity purification of hybridoma antibodies |
| US5849874A (en) | 1991-07-12 | 1998-12-15 | Gist-Brocades, N.V. | Process for the purification of serum albumin |
| JP2825755B2 (ja) * | 1993-04-07 | 1998-11-18 | 大塚製薬株式会社 | ピペリジン誘導体を有効成分とする末梢血管拡張剤および新規ピペリジン誘導体 |
| JPH09511492A (ja) * | 1994-02-03 | 1997-11-18 | ザ ピコワー インスティテュート フォア メディカル リサーチ | アミロイドーシスの前進性グリコシル化終末産物仲介モジュレーション用組成物及び方法 |
| GB9914825D0 (en) * | 1999-06-24 | 1999-08-25 | Smithkline Beecham Spa | Novel compounds |
| EP1162196A4 (en) | 1999-12-27 | 2003-04-16 | Japan Tobacco Inc | COMPOUNDS WITH JOINED CYCLES AND THEIR USE AS MEDICAMENTS |
| DE10139416A1 (de) * | 2001-08-17 | 2003-03-06 | Aventis Pharma Gmbh | Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| GB2403222A (en) | 2002-04-01 | 2004-12-29 | Utah Ventures Ii L P | Tissue-specific endothelial membrane proteins |
| ATE425753T1 (de) * | 2002-08-02 | 2009-04-15 | Genesoft Pharmaceuticals Inc | Biaryl-verbindungen mit antiinfektiver wirkung |
| US7777051B2 (en) | 2003-05-13 | 2010-08-17 | Icagen, Inc. | Asymmetric benzimidazoles and related compounds as potassium channel modulators |
| EP1960382A1 (en) | 2005-11-03 | 2008-08-27 | ChemBridge Research Laboratories, Inc. | Heterocyclic compounds as tyrosine kinase modulators |
| CN102573913B (zh) | 2009-07-31 | 2014-06-18 | 阿森迪斯药物股份有限公司 | 可生物降解的基于聚乙二醇的水不溶性水凝胶 |
| US8614238B2 (en) * | 2009-10-19 | 2013-12-24 | Boehringer Ingelheim International Gmbh | Cyclopentanecarboxamide derivatives, medicaments containing such compounds and their use |
| KR102008946B1 (ko) * | 2010-08-03 | 2019-08-08 | 노브알리스 도이칠란트 게엠베하 | 친화성 크로마토그래피에 의한 항체 및 Fc-융합 단백질 정제용 리간드 |
| WO2012020080A2 (en) | 2010-08-12 | 2012-02-16 | Graffinity Pharmaceuticals Gmbh | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY II |
| WO2012140647A2 (en) | 2011-04-11 | 2012-10-18 | Yeda Research And Development Co. Ltd | Albumin binding probes and drug conjugates thereof |
| UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| EP2752426A1 (en) | 2013-01-03 | 2014-07-09 | Covagen AG | Human serum albumin binding compounds and fusion proteins thereof |
-
2014
- 2014-10-01 WO PCT/IB2014/064998 patent/WO2015049651A1/en not_active Ceased
- 2014-10-01 CN CN201480054551.4A patent/CN105593222B/zh not_active Expired - Fee Related
- 2014-10-01 JP JP2016519325A patent/JP2016534984A/ja active Pending
- 2014-10-01 US US15/026,725 patent/US9809558B2/en not_active Expired - Fee Related
- 2014-10-01 ES ES14786355T patent/ES2721098T3/es active Active
- 2014-10-01 AU AU2014330781A patent/AU2014330781B2/en not_active Ceased
- 2014-10-01 EP EP14786355.9A patent/EP3052483B1/en active Active
- 2014-10-01 BR BR112016007371A patent/BR112016007371A2/pt not_active Application Discontinuation
- 2014-10-01 RU RU2016117052A patent/RU2016117052A/ru not_active Application Discontinuation
- 2014-10-01 CA CA2925862A patent/CA2925862A1/en not_active Abandoned
- 2014-10-01 KR KR1020167008267A patent/KR20160060660A/ko not_active Withdrawn
- 2014-10-01 SG SG11201601870VA patent/SG11201601870VA/en unknown
-
2017
- 2017-09-07 US US15/698,020 patent/US9938243B2/en active Active
Non-Patent Citations (1)
| Title |
|---|
| FRISCHKORN, H. et al., ‘Naphthylendi(heteroarene), III. Synthese und spektroskopisches Verhalten von 2,2’-Naphthylendibenzazolen’, Liebigs Annalen der Chemie, 1984, No. 6, pages 1129-1136 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105593222A (zh) | 2016-05-18 |
| US20170369448A1 (en) | 2017-12-28 |
| CN105593222B (zh) | 2018-02-09 |
| ES2721098T3 (es) | 2019-07-26 |
| EP3052483A1 (en) | 2016-08-10 |
| US9809558B2 (en) | 2017-11-07 |
| WO2015049651A1 (en) | 2015-04-09 |
| BR112016007371A2 (pt) | 2017-08-01 |
| RU2016117052A (ru) | 2017-11-10 |
| US9938243B2 (en) | 2018-04-10 |
| JP2016534984A (ja) | 2016-11-10 |
| AU2014330781A1 (en) | 2016-04-07 |
| RU2016117052A3 (https=) | 2018-06-27 |
| US20160221962A1 (en) | 2016-08-04 |
| EP3052483B1 (en) | 2019-02-06 |
| SG11201601870VA (en) | 2016-04-28 |
| CA2925862A1 (en) | 2015-04-09 |
| KR20160060660A (ko) | 2016-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014330781B2 (en) | Compounds for affinity chromatography and for extending the half-life of a therapeutic agent | |
| Hofstee | Hydrophobic affinity chromatography of proteins | |
| Zheng et al. | Monoliths with proteins as chiral selectors for enantiomer separation | |
| US20180223003A1 (en) | Novel Chelator and Use Thereof | |
| JP6524272B2 (ja) | 両性イオン性試薬 | |
| CN105838355B (zh) | 一类小分子荧光探针及其应用 | |
| WO2015041218A1 (ja) | 新規抗体精製方法及びそれから得られる抗体（Ｎｏｖｅｌ Ａｎｔｉｂｏｄｙ Ｐｕｒｉｆｉｃａｔｉｏｎ Ｍｅｔｈｏｄ ａｎｄ Ａｎｔｉｂｏｄｙ ｏｂｔａｉｎｅｄ ｔｈｅｒｅｆｒｏｍ）、並びに陽イオン交換基を用いた新規抗体精製法及びそれから得られる抗体（Ｎｏｖｅｌ Ａｎｔｉｂｏｄｙ Ｐｕｒｉｆｉｃａｔｉｏｎ ｍｅｔｈｏｄ ｕｓｉｎｇ Ｃａｔｉｏｎ Ｅｘｃｈａｎｇｅｒ ａｎｄ Ａｎｔｉｂｏｄｙ ｏｂｔａｉｎｅｄ ｔｈｅｒｅｆｒｏｍ） | |
| CN102834415A (zh) | 亲和色谱用填充剂以及离析免疫球蛋白的方法 | |
| US7335768B2 (en) | Cucurbit [n] uril compounds and analogs, and methods of making and using the same | |
| AU2006272714A1 (en) | Compositions and methods for protein deaggregation | |
| JP4750035B2 (ja) | 光切断型リンカーを利用したリガンド固定化固相担体 | |
| CN105301230B (zh) | 一种基于疏水性电荷诱导磁性微球的抗体荧光标记方法 | |
| AU2024230594A1 (en) | Photoswitchable compounds and affinity ligands, and their use for the optical control of affinity matrices | |
| CN103923217B (zh) | 6-氨基己酸纤维素酯及其合成方法和应用 | |
| WO2009043899A1 (en) | Drug transfer into living cells | |
| JP2023513285A (ja) | 生体物質と連結し得る両性蛍光物質 | |
| JP2001527090A (ja) | アルブミンを結合する方法およびその方法で使用すべき手段 | |
| US20240024493A1 (en) | Purification methods for large scale synthesis of cucurbit[7]uril-peg conjugates | |
| US20230382946A1 (en) | Polypeptide or protein directional modification method based on sulfhydryl-alkenyl azide coupling | |
| JP2019058885A (ja) | 吸着材及び標的物質の精製方法 | |
| JPH0767692A (ja) | 光学異性体用分離剤 | |
| Nazzal et al. | Fmoc Solid-Phase FIT-PNA Synthesis—Manual and Automated Methodologies | |
| CN106928093A (zh) | 氰基非天然氨基酸的制备及其在生物正交拉曼检测上的应用 | |
| KR20210106418A (ko) | 다이머 펩타이드-인지질 콘쥬게이트를 위한 최적화 과정 | |
| BR112021011717A2 (pt) | Substrato funcionalizado por ligante, método para a preparação do substrato funcionalizado por ligante, e, uso de um substrato funcionalizado por ligante |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |